News

Molecular Devices and Cytena Partner to Launch the CloneSelect Single-Cell Printer

Announcing the Single-Cell Printer for documented isolation of cells in clonal cell line development

Sunnyvale, California and Freiburg, Germany – September 19, 2017 – Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel system utilizes sophisticated microfluidics-based technology and real-time image analysis to isolate single cells and provide visual documentation of monoclonality for use in cell line development.
Clonal cell line development has been receiving increasing focus and investment as a method for producing targeted therapeutics. As a part of the development process, cells producing high amounts of the antibody of interest need to be selectively isolated to be able to move them forward for additional screening. The CloneSelect SCP accelerates antibody discovery by allowing for automated isolation of single cells into standard 96- and 384- well plates for a wide range of cell types.

“We are very excited about this product and how it allows us to expand our toolset in the fast-growing biotherapeutics market,” said Greg Milosevich, President at Molecular Devices. “Our customers have been seeking ways to bring biologics and biosimilars to market more quickly, and we continue to invest in technologies that accelerate time-consuming process steps.”

Traditional methods for single cell sorting in cell line development suffer from drawbacks including low sorting efficiencies, low cell viabilities, and limited evidence of monoclonality. The CloneSelect SCP overcomes these limitations by screening for both single cells and for cell morphology immediately prior to gently depositing in the well, ensuring high cell viability. The use of sterilized, disposable cartridges also ensures the prevention of any cross-contamination or need for in-situ sterilization. During deposition, images of single cells are provided, giving customers the confidence of knowing their cell lines are monoclonal.

“This partnership will accelerate the continued growth of our business,” said Jonas Schoendube, CEO at Cytena. “We are looking forward to having additional commercial capabilities in the United States and Canada as a result of our work with Molecular Devices, and we believe that this relationship will bring superior service to our customer base.”

About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables and is dedicated to helping customers unravel the complexity of biological systems. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These innovative instruments, combined with scientific expertise, assays, and analytics tools for protein and cell biology enable scientists to explore life’s most important questions. The company is headquartered in Silicon Valley, California with offices around the globe.

About cytena, GmbH
Cytena GmbH is an established start-up in the field of life science, founded in 2014 in Freiburg, Germany and focuses on single-cell technologies. The Cytena team has developed the patented single-cell printing technology that enables deposition of single cells in a documented, viable and sterile workflow. The Single-Cell Printers™ are manufactured in Germany and marketed worldwide. In 2017, the majority of the top ten pharma companies use Single-Cell Printers to ensure fast antibody development.

For more information, visit: www.moleculardevices.com/CloneSelectSCP
or www.cytena.com

Contact Information for Molecular Devices:
Sarah Vargas-Hurlston
Director of Marketing, Drug Discovery
+1 408.203.8692
sarah.vargas-hurlston@moldev.com

Contact Information for Cytena GmbH:
Benjamin Steimle
CFO
+49 761 203 732 19
steimle@cytena.com

Read the press release: PDF

Read more:

 

cytena raises 1.1 Mio. EUR seed capital!

 

cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.

Freiburg / April 2015 – The cy-Clone, cytena’s newest innovation, is a laboratory device that enables the gentle separation of cells. In order to set up its marketing and distribution channels and to standardize its production processes, the company required start-up capital. “During our fundraising we greatly benefitted from the fact that since 2010 our laboratory units have helped a number of our partners to simplify their processes. In addition, cytena has already been generating revenue”, says Jonas Schöndube, founding member and managing director of cytena, adding, “This very convincingly proved that there is a real need for our technology.”

The seed capital raised will enable the company to make the most of their technological advantage over competing technologies and to transition from producing each cy-Clone unit and its consumables individually to serial production. At the same time, cytena’s marketing and distribution channels will be widened more rapidly.

“Currently, we are in particularly close contact with cell line development units in the pharmaceutical industry e. g. for biologicals and with researchers in the field of single-cell analyses. Obviously, efficiency and cell viability are key, but quite often these customers also need to fulfill the requirements set by regulatory bodies such as the FDA,” says André Gross, founding member and technical director of cytena. “Our competitors’ systems are complex and expensive, and cannot prove clonality or safeguard against cross-contamination. In addition, a substantial amount of training is required to operate them. Users wanting to avoid all of these complications and inconveniences should use our unique technology.”

“The global market potential for single-cell technologies is estimated to top EUR 360 million. Moving forward, cytena will focus on further developing the platform technology for cancer and prenatal testing units as well as units for the production of cell therapeutic drugs. These areas of application will unlock a much larger market,” says Dr. Sebastian Schöfer, explaining HTGF’s reasoning to invest.

About cytena GmbH

For the past four years, Jonas Schöndube and André Gross, two engineers from Freiburg, have been focussing on single-cell printing technologies. They partnered with the inventor of the technology Dr. Peter Koltay, economist Benjamin Steimle and BioFluidix GmbH to found cytena, a University of Freiburg spin-off company sponsored by the German federal support program EXIST.

Single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research. The cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. Thanks to this particularly gentle delivery method, the cells are able to survive post printing and can either be analyzed thereafter or grown into clonal colonies. To determine clonality, multiple images are recorded during the process. Cross-contamination is avoided by the use of disposable parts.

Media contact details:

cytena GmbH, Benjamin Steimle
Georges-Koehler-Allee 103
79110 Freiburg, Germany
0049 761 203 732 19
steimle@cytena.com
www.cytena.com

About High-Tech Gruenderfonds

High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).

Contact:

High-Tech Gründerfonds Management GmbH
Schlegelstraße 2
53113 Bonn
Dr. Sebastian Schöfer
Tel: +49 (228) 823 00-100
Fax: +49 (228) 823 000-50
s.schoefer@htgf.de
www.high-tech-gruenderfonds.de


Read the press release: PDF